Cencora Inc. stock gains on strong fiscal Q3 2026 earnings and higher guidance

Published on 09/15/2026 at 13:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cencora Inc. stock reflects solid fiscal third-quarter 2026 results with revenue up 5.1 percent and adjusted EPS rising to 4.48 dollars as of August 5, 2026. The company also raised its fiscal 2026 adjusted EPS guidance to a range of 17.75 to 17.95 dollars and continues a 0.60 dollar quarterly dividend.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora Inc. stock (ISIN US15135B1017) is trading firmly supported by strong fiscal third-quarter 2026 earnings, with revenue up 5.1 percent year over year to USD 84.8 billion and adjusted diluted EPS rising to USD 4.48 as reported on August 5, 2026, compared with USD 4.00 a year earlier according to StockTitan.

Fiscal Q3 2026 results drive earnings momentum

According to StockTitan on August 5, 2026, Cencora generated fiscal third-quarter 2026 revenue of USD 84.8 billion, an increase of 5.1 percent compared with the same quarter of the prior year, while gross profit rose 24.1 percent to USD 3.6 billion.

In the same report, GAAP diluted EPS for fiscal third-quarter 2026 increased to USD 3.94 from USD 3.52 in the prior-year quarter, and adjusted diluted EPS improved to USD 4.48 from USD 4.00, highlighting earnings growth of 12.0 percent on an adjusted basis according to StockTitan.

Guidance raised and capital allocation remains active

Cencora has raised and reaffirmed its fiscal 2026 adjusted diluted EPS guidance to a range of USD 17.75 to USD 17.95, up from a prior range of USD 17.65 to USD 17.90, signaling confidence in earnings growth for the full fiscal year 2026 according to StockTitan.

In the fiscal third quarter 2026 disclosure, the company projected adjusted operating income growth of 13 to 14 percent for fiscal 2026, revenue growth in a 4 to 6 percent range, and adjusted free cash flow of about USD 3.0 billion, with approximately USD 900 million in capital expenditures according to StockTitan.

Dividend and share repurchases support shareholder returns

Alongside its earnings release, Cencora declared a quarterly dividend of USD 0.60 per share payable on August 31, 2026, which equates to an annualized dividend of USD 2.40 and reflects a continued distribution policy according to StockTitan.

The same filing indicates that Cencora repurchased USD 1.0 billion of its own shares during the fiscal third quarter 2026, reinforcing the role of buybacks in its capital allocation strategy according to StockTitan.

Stock performance and valuation backdrop

Recent commentary notes that Cencora stock opened at USD 326.67 on a recent trading day in mid-September 2026 on the New York Stock Exchange, with sell-side analysts expecting full-year fiscal 2026 EPS of approximately USD 17.87, close to the company’s own adjusted EPS guidance range according to MarketBeat.

As of that same MarketBeat overview dated September 15, 2026, the consensus analyst rating on Cencora stands at Moderate Buy, with an average price target of USD 370.85, which implies upside of roughly 13.6 percent compared with the USD 326.67 opening level according to MarketBeat.

Risks around growth mix and international exposure

An analysis published on September 15, 2026 highlights that Cencora’s long-term narrative is built on expected revenue growth of about 5.8 percent per year and an increase in earnings from roughly USD 2.6 billion today to USD 3.4 billion by 2029, but flags the risk that a mix shift toward higher-margin services might not progress quickly enough to offset pressure from lower-fee categories and international softness according to Simply Wall St.

The same Simply Wall St piece notes that Cencora’s current valuation implies a potential upside of about 14 percent to its estimated fair value, broadly consistent with the gap between the recent share price and the consensus analyst price target, but reiterates that execution on new initiatives such as cell and gene therapy support will be important for realizing that potential according to Simply Wall St.

Stock level as of mid-September 2026

Based on recent New York Stock Exchange data referenced by MarketBeat on September 15, 2026, Cencora Inc. stock opened at USD 326.67, with analysts’ average price target of USD 370.85 suggesting mid-teens percentage upside from that level, while the shares continue to be classified within the S&P 500 healthcare segment, positioning the company among large-cap healthcare distributors in the United States according to MarketBeat.